Aktis Oncology, Inc.
AKTS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$27.05
▲ +1.50%
P/E
-21.13
Mkt Cap
$1.4B
52-Wk Range
$14.72–$34.19
52-Week Range
$14.72 - $34.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 20.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary miniprotein radioconjugate platform with superior tumor penetration versus antibodies
- Multiple clinical-stage assets targeting high-prevalence cancer indications
- Differentiated radiopharmaceutical approach in growing targeted radionuclide therapy market
- Experienced oncology and radiopharmaceutical development team
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Strong growth ahead
Clinical trial advancement and potential FDA approvals for AKY-1189 and AKY-2519
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+42.6% over 3m
Quality
Excellent
High-growth business (100% revenue growth, 85% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying AKTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.44 vs -$0.43 consensus (-2.2% surprise). Revenue of $3.4M vs $2.7M expected (+25.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.2%
Revenue trend · last 4Q
—
+100%
—
—
Q4 24
Q4 25
Q1 26
Q2 26
$933.0K
$1.9M
$3.2M
$3.4M
Margins · last 4Q
Gross
74.0%
Profit
-713.5%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · Jun 15, 2026
vs Industry
How AKTS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related